Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2015

Open Access 01-12-2015 | Research article

Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis

Authors: Cornelius Remschmidt, Ole Wichmann, Thomas Harder

Published in: BMC Medicine | Issue 1/2015

Login to get access

Abstract

Background

Patients with diabetes are at increased risk of severe influenza disease; influenza vaccination for these patients is therefore recommended by the World Health Organization and several National Immunization Technical Advisory Groups. However, no systematic review has evaluated the effects of influenza vaccines for patients with diabetes.

Methods

We conducted a systematic review and meta-analysis by searching Medline, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from inception until November 2014. We included all types of studies reporting on the efficacy, effectiveness, and/or safety of influenza vaccination in patients with type 1 and type 2 diabetes of all ages. We used the Newcastle-Ottawa scale to assess risk of bias in observational studies. Residual confounding was addressed by comparing estimates of vaccine effectiveness (VE) during influenza seasons to those obtained during off-seasons. Quality of the evidence for each outcome was assessed using the GRADE methodology.

Results

Following review of 1,444 articles, 11 observational studies with a total of 170,924 participants were included. In diabetic patients of working-age (18–64 years), influenza vaccination prevented all-cause hospitalization with a pooled VE of 58% (95% CI, 6–81%) and hospitalization due to influenza or pneumonia (VE 43%; 95% CI, 28–54%), whereas no effects on all-cause mortality and influenza-like illness (ILI) were observed. In the elderly (65+), influenza vaccination prevented all-cause mortality (VE 38%; 95% CI, 32–43%), all-cause hospitalization (VE 23%; 95% CI, 1–40%), hospitalization due to influenza or pneumonia (VE 45%; 95% CI, 34–53%), and ILI (VE 13%; 95% CI, 10–16%). However, significant off-season estimates for several outcomes indicated residual confounding, particularly in elderly patients. Quality of the evidence was low to very low for all outcomes. Laboratory-confirmed influenza infections were not reported.

Conclusions

Due to strong residual confounding in most of the identified studies, the available evidence is insufficient to determine the magnitude of benefit that diabetic people derive from seasonal influenza vaccination. Adequately powered randomized controlled trials or quasi-experimental studies using laboratory-confirmed influenza-specific outcomes are urgently needed.
Appendix
Available only for authorised users
Literature
1.
Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40.CrossRefPubMed
2.
Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061.CrossRefPubMedPubMedCentral
3.
4.
Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices – United States, 2013–2014. MMWR Recomm Rep. 2013;62:1–43.
5.
6.
7.
8.
Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281–8.CrossRefPubMed
9.
Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26:510–3.CrossRefPubMed
10.
11.
Yende S, van der Poll T, Lee M, Huang DT, Newman AB, Kong L, et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax. 2010;65:870–7.CrossRefPubMedPubMedCentral
12.
Collaboration ERF, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.CrossRef
13.
Diepersloot RJ, Bouter KP, Beyer WE, Hoekstra JB, Masurel N. Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologia. 1987;30:397–401.CrossRefPubMed
14.
Muszkat M, Friedman G, Dannenberg HD, Greenbaum E, Lipo M, Heymann Y, et al. Response to influenza vaccination in community and in nursing home residing elderly: relation to clinical factors. Exp Gerontol. 2003;38:1199–203.CrossRefPubMed
15.
Frasca D, Diaz A, Romero M, Mendez NV, Landin AM, Ryan JG, et al. Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine. 2013;31:3603–10.CrossRefPubMedPubMedCentral
16.
Pozzilli P, Gale EA, Visalli N, Baroni M, Crovari P, Frighi V, et al. The immune response to influenza vaccination in diabetic patients. Diabetologia. 1986;29:850–4.CrossRefPubMed
17.
Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS. 1997;8:776–9.CrossRefPubMed
18.
El-Madhun AS, Cox RJ, Seime A, Sovik O, Haaheim LR. Systemic and local immune responses after parenteral influenza vaccination in juvenile diabetic patients and healthy controls: results from a pilot study. Vaccine. 1998;16:156–60.CrossRefPubMed
19.
Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines. 2013;12:519–36.CrossRefPubMed
20.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9. W264.CrossRefPubMed
21.
Heymann AD, Shapiro Y, Chodick G, Shalev V, Kokia E, Kramer E, et al. Reduced hospitalizations and death associated with influenza vaccination among patients with and without diabetes. Diabetes Care. 2004;27:2581–4.CrossRefPubMed
22.
23.
24.
Guyatt GH, Oxman AD, Schunemann HJ. GRADE guidelines-an introduction to the 10th-13th articles in the series. J Clin Epidemiol. 2013;66:121–3.CrossRefPubMed
25.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.CrossRefPubMedPubMedCentral
26.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.CrossRefPubMed
27.
Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–2.CrossRefPubMed
28.
Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol. 2013;66:173–83.CrossRefPubMed
29.
Hak E, Nordin J, Wei F, Mullooly J, Poblete S, Strikas R, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002;35:370–7.CrossRefPubMed
30.
Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;2:CD004876.PubMed
31.
Isotani H. Use of influenza vaccine in patients with diabetes, particularly those with complications of cardiac or renal disease. Intern Med. 2000;39:862.CrossRefPubMed
32.
Rodriguez-Blanco T, Vila-Corcoles A, de Diego C, Ochoa-Gondar O, Valdivieso E, Bobe F, et al. Relationship between annual influenza vaccination and winter mortality in diabetic people over 65 years. Hum Vaccin Immunother. 2012;8:363–70.CrossRefPubMed
33.
Selvais PL, Hermans MP, Donckier JE, Buysschaert M. Reported rates, incentives, and effectiveness of major vaccinations in 501 attendees at two diabetes clinics. Diabetes Care. 1997;20:1212–3.CrossRefPubMed
34.
Schade CP, McCombs MA. Influenza immunization and mortality among diabetic Medicare beneficiaries in West Virginia. W V Med J. 2000;96:444–8.PubMed
35.
Lau D, Eurich DT, Majumdar SR, Katz A, Johnson JA. Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study. Thorax. 2013;68:658–63.CrossRefPubMedPubMedCentral
36.
Colquhoun AJ, Nicholson KG, Botha JL, Raymond NT. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect. 1997;119:335–41.CrossRefPubMedPubMedCentral
37.
Gasparini R, Amicizia D, Lai PL, Rossi S, Panatto D. Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V (R) and Fluad (R)) in preventing hospitalization for influenza and pneumonia in the elderly: a matched case–control study. Hum Vaccin Immunother. 2013;9:144–52.CrossRefPubMed
38.
Looijmans-Vanden Akker I, Verheij TJ, Buskens E, Nichol KL, Rutten GE, Hak E. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care. 2006;29:1771–6.CrossRef
39.
Wang IK, Lin CL, Chang YC, Lin PC, Liang CC, Liu YL, et al. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. Vaccine. 2013;31:718–24.CrossRefPubMed
40.
Dahlquist GG, Nystrom L, Patterson CC, Swedish Childhood Diabetes Study Group, Diabetes Incidence in Sweden Study Group. Incidence of type 1 diabetes in Sweden among individuals aged 0–34 years, 1983–2007: an analysis of time trends. Diabetes Care. 2011;34:1754–9.CrossRefPubMedPubMedCentral
41.
Ehehalt S, Dietz K, Willasch AM, Neu A. Baden-Wurttemberg Diabetes Incidence Registry Group. Epidemiological perspectives on type 1 diabetes in childhood and adolescence in Germany: 20 years of the Baden-Wurttemberg Diabetes Incidence Registry (DIARY). Diabetes Care. 2010;33:338–40.CrossRefPubMed
42.
Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G, EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet. 2009;373:2027–33.CrossRefPubMed
43.
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49.CrossRefPubMed
44.
Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2014;3:CD001269.
45.
Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, et al. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Vaccine. 2009;27:5357–62.CrossRefPubMed
46.
Vistoli F, Focosi D, De Donno M, Giannecchini S, Mariotti ML, Occhipinti M, et al. Pancreas rejection after pandemic influenza virus A(H1N1) vaccination or infection: a report of two cases. Transpl Int. 2011;24:e28–9.CrossRefPubMed
47.
Yasuda H, Nagata M, Moriyama H, Kobayashi H, Akisaki T, Ueda H, et al. Development of fulminant Type 1 diabetes with thrombocytopenia after influenza vaccination: a case report. Diabet Med. 2012;29:88–9.CrossRefPubMed
48.
Kissling E, Valenciano M, Falcao J, Larrauri A, Widgren K, Pitigoi D, et al. ‘I-MOVE’ towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case–control study in Europe, 2008–9. Euro Surveill. 2009;14:19388.PubMed
49.
Navarro-Mari JM, Perez-Ruiz M, Cantudo-Munoz P, Petit-Gancedo C, Jimenez-Valera M, Rosa-Fraile M, et al. Influenza-like illness criteria were poorly related to laboratory-confirmed influenza in a sentinel surveillance study. J Clin Epidemiol. 2005;58:275–9.CrossRefPubMed
50.
Woolpert T, Brodine S, Lemus H, Waalen J, Blair P, Faix D. Determination of clinical and demographic predictors of laboratory-confirmed influenza with subtype analysis. BMC Infect Dis. 2012;12:129.CrossRefPubMedPubMedCentral
51.
Thomas RE. Is influenza-like illness a useful concept and an appropriate test of influenza vaccine effectiveness? Vaccine. 2014;32:2143–9.CrossRefPubMed
52.
Hak E, Verheij TJ, Grobbee DE, Nichol KL, Hoes AW. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Community Health. 2002;56:951–5.CrossRefPubMedPubMedCentral
53.
Ridenhour BJ, Campitelli MA, Kwong JC, Rosella LC, Armstrong BG, Mangtani P, et al. Effectiveness of inactivated influenza vaccines in preventing influenza-associated deaths and hospitalizations among Ontario residents aged ≥65 years: estimates with generalized linear models accounting for healthy vaccinee effects. PLoS One. 2013;8:e76318.CrossRefPubMedPubMedCentral
54.
Jackson ML, Yu O, Nelson JC, Naleway A, Belongia EA, Baxter R, et al. Further evidence for bias in observational studies of influenza vaccine effectiveness: the 2009 influenza A(H1N1) pandemic. Am J Epidemiol. 2013;178:1327–36.CrossRefPubMed
55.
Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol. 2006;35:337–44.CrossRefPubMed
56.
Beyer WE. Heterogeneity of case definitions used in vaccine effectiveness studies and its impact on meta-analysis. Vaccine. 2006;24:6602–4.CrossRefPubMed
57.
Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007;357:1373–81.CrossRefPubMed
58.
Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine. 2002;20:1831–6.CrossRefPubMed
59.
Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007;7:658–66.CrossRefPubMed
60.
Nohynek H, Wichmann O, D Ancona F, VENICE National Gatekeepers. National Advisory Groups and their role in immunization policy-making processes in European countries. Clin Microbiol Infect. 2013;19:1096–105.CrossRefPubMed
61.
Wong K, Campitelli MA, Stukel TA, Kwong JC. Estimating influenza vaccine effectiveness in community-dwelling elderly patients using the instrumental variable analysis method. Arch Intern Med. 2012;172:484–91.CrossRefPubMed
Metadata
Title
Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis
Authors
Cornelius Remschmidt
Ole Wichmann
Thomas Harder
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2015
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-015-0295-6

Other articles of this Issue 1/2015

BMC Medicine 1/2015 Go to the issue

Tutorial

How to spot a statistical problem: advice for a non-statistical reviewer

Research article

Health and wealth in Mesoamerica: findings from Salud Mesomérica 2015

Commentary

De-adoption and its 43 related terms: harmonizing low-value care terminology

Research article

The evolution of mobile apps for asthma: an updated systematic assessment of content and tools

Commentary

‘Trust but verify’ – five approaches to ensure safe medical apps

Research article

Ready-to-use therapeutic food with elevated n-3 polyunsaturated fatty acid content, with or without fish oil, to treat severe acute malnutrition: a randomized controlled trial